中医“治未病”思想指导慢性胃炎“炎-癌”转化防治的思考与实践

姚欣凝; 李园; 丁霞

doi:10.3969/j.issn.1671-038X.2024.06.09

中医“治未病”思想指导慢性胃炎“炎-癌”转化防治的思考与实践

- 1.
  北京中医药大学东直门医院脾胃病科(北京，100700)
- 2.
  北京中医药大学国家中医体质与治未病研究院
- 3.
  北京中医药大学中医学院
基金项目:
国家自然科学基金面上项目(No：82374292)

详细信息

通讯作者: 丁霞，E-mail：dingx@bucm.edu.cn

中图分类号: R256.3

收稿日期: 2024-03-15

刊出日期: 2024-06-15

Prevention and treatment of "inflammation-cancer" transformation of chronic gastritis based on the theory of Traditional Chinese Medicine "preventive treatment of disease"

- 1.
  Department of Spleen and Stomach Diseases, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China
- 2.
  National Institute of Traditional Chinese Medicine Constitution and Preventive Medicine, Beijing University of Chinese Medicine
- 3.
  College of Traditional Chinese Medicine, Beijing University of Chinese Medicine

More Information

Corresponding author: DING Xia, E-mail: dingx@bucm.edu.cn

Received Date: 15 March 2024

Publish Date: 15 June 2024

摘要

摘要: 中医“治未病”思想对于胃“炎-癌”转化的防治具有重要的指导意义，应将“既病防变”思想贯穿胃“炎-癌”转化全过程，时刻将“防变”作为治疗的目标，形成胃“炎-癌”转化全链条防治策略：早识恶性进展之先兆，防微杜渐，欲病救萌；在把握动态演变规律的前提下，抓住最佳时机，改变“重治疗、轻预防”的诊疗模式，化“被动”为“主动”，积极主动进行干预；同时摄生护胃，调养脾胃生理功能。同时，基于“既病防变”思想防治胃“炎-癌”转化还存在着难点问题，如缺乏连续、动态、全过程的评价体系和对胃“炎-癌”转化防治的全程管理。可通过建立连续、动态的整合研究体系，以讲清楚、说明白中医药防治胃“炎-癌”转化的作用机制，建立胃“炎-癌”转化全病程专病一体化智能管理平台，实现对患者的全病程管理并获取更多循证证据。
- 治未病 /
- 慢性胃炎 /
- “炎-癌”转化 /
- 中医药 /
- 防治
Abstract: The idea of "preventive treatment of disease" in Traditional Chinese Medicine(TCM) has important guiding significance for the prevention and treatment of "inflammation-cancer" transformation. The idea of "preventing disease from changing" should be run through the whole process of "inflammation-cancer" transformation, and "preventing disease from changing" should be taken as the goal of treatment at all times to form the whole chain prevention and treatment strategy of "inflammation-cancer" transformation: early recognition of the omen of malignant progress, prevention of micro-progression, and rescue of disease; on the premise of grasping the law of dynamic evolution, we should seize the best opportunity to change the diagnosis and treatment mode of "heavy treatment, light prevention", turn "passive" into "active", and actively intervene; at the same time, it protects the stomach and regulates the physiological function of the spleen and stomach. At the same time, there are still difficult problems in the prevention and treatment of "inflammation-cancer" transformation based on the idea of "preventing the transformation of both diseases", such as the lack of continuous, dynamic and whole-process evaluation system and the whole-process management of the prevention and treatment of "inflammation-cancer" transformation. Through the establishment of a continuous and dynamic integrated research system, we can clarify and explain the mechanism of TCM in the prevention and treatment of "inflammation-cancer" transformation, and establish an integrated intelligent management platform for the whole course of "inflammation-cancer" transformation, so as to realize the whole course management of patients and obtain more evidence-based evidence.
- preventive treatment of disease /
- chronic gastritis /
- "inflammation-cancer" transformation /
- Traditional Chinese Medicine /
- prevention and treatment

HTML全文

参考文献(29)

[1]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL202311001.htm
[2]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. doi: 10.1016/S0140-6736(17)33326-3
[3]	马乾宸, 张本炎, 芮炜玮, 等. 中国3 071例胃癌病理分型分析[J]. 诊断学理论与实践, 2022, 21(5): 560-566. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDLS202205003.htm
[4]	Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention[J]. Cancer Res, 1992, 52(24): 6735-6740.
[5]	王琦. 中医未病学[M]. 北京: 中国中医药出版社, 2015: 1-6.
[6]	王琦. 中医治未病解读[M]. 北京: 中国中医药出版社, 2007: 1-32.
[7]	Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J National Cancer Center, 2022, 2(1): 1-9. doi: 10.1016/j.jncc.2022.02.002
[8]	房静远, 杜奕奇, 刘文忠, 等. 中国慢性胃炎诊治指南(2022年, 上海)[J]. 胃肠病学, 2023, 28(3): 149-180. https://www.cnki.com.cn/Article/CJFDTOTAL-WIEC202303004.htm
[9]	赵建业, 朱春平, 李兆申. 血清胃蛋白酶原、胃泌素-17、幽门螺杆菌抗体检测对萎缩性胃炎和胃癌的诊断价值[J]. 胃肠病学, 2016, 21(6): 376-379. https://www.cnki.com.cn/Article/CJFDTOTAL-WIEC201606015.htm
[10]	苏泽琦, 张文君, 张雨珊, 等. 慢性胃炎恶性转化过程证候、证素演变规律[J]. 现代中医临床, 2017, 24(6): 9-14. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYL201706003.htm
[11]	International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori[J]. IARC Monogr Eval Carcinog Risks Hum, 1994, 61: 1-241.
[12]	王萍, 李鹏, 陈萦晅, 等. 中国整合胃癌前病变临床管理指南[J]. 胃肠病学, 2021, 26(2): 91-111. https://www.cnki.com.cn/Article/CJFDTOTAL-WIEC202102005.htm
[13]	Chen HN, Wang Z, Li X, et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis[J]. Gastric Cancer, 2016, 19(1): 166-175. doi: 10.1007/s10120-015-0462-7
[14]	Li WQ, Zhang JY, Ma JL, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial[J]. BMJ, 2019, 366: 15016.
[15]	Yan L, Chen Y, Chen F, et al. Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up[J]. Gastroenterology, 2022, 163(1): 154-162. e3. doi: 10.1053/j.gastro.2022.03.039
[16]	苏泽琦, 于春月, 张文君, 等. 国医大师路志正治疗慢性萎缩性胃炎临证经验[J]. 现代中医临床, 2017, 24(3): 34-36. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYL201703010.htm
[17]	Li Y, Li T, Chen JN, et al. Manpixiao Decoction Halted the Malignant Transformation of Precancerous Lesions of Gastric Cancer: From Network Prediction to In-Vivo Verification[J]. Front Pharmacol, 2022, 13: 927731. doi: 10.3389/fphar.2022.927731
[18]	赫捷, 陈万青, 李兆申, 等. 中国胃癌筛查与早诊早治指南(2022, 北京)[J]. 中国肿瘤, 2022, 31(7): 488-527. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU202207009.htm
[19]	龚雪妍. 慢性胃炎发病与饮食的相关性研究[D]. 北京: 北京中医药大学, 2016.
[20]	张雨珊. 慢性胃炎患者饮食干预研究[D]. 北京: 北京中医药大学, 2018.
[21]	刘洁, 韩川, 张剑, 等. 慢性胃炎患者300例的精神心理特征分析[J]. 中华消化杂志, 2020, 40(3): 186-191.
[22]	于春月, 刘婷, 刘凯歌, 等. 慢性萎缩性胃炎病证结合动物模型的建立与评价[J]. 中华中医药杂志, 2018, 33(5): 2140-2144. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201805099.htm
[23]	丁霞, 苏泽琦, 沈洪, 等. 慢性胃炎"炎癌转化"病证结合大鼠模型建立中的难点问题及应对策略[J]. 北京中医药大学学报, 2020, 43(12): 973-979. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYB202012001.htm
[24]	李涛, 宋晓玉, 褚福浩, 等. 胃癌类器官的建立及应用研究进展[J]. 中国细胞生物学学报, 2020, 42(9): 1624-1630. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZZ202009016.htm
[25]	Wang Y, Chu FH, Lin J, et al. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer(PLGC)through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification[J]. J Ethnopharmacol, 2021, 279: 114399. doi: 10.1016/j.jep.2021.114399
[26]	李萍. 慢性胃炎患者5年疾病演变随访及相关影响因素研究[D]. 北京: 北京中医药大学, 2020.
[27]	Dilaghi E, Lahner E, Annibale B, et al. Systematic review and meta-analysis: Artificial intelligence for the diagnosis of gastric precancerous lesions and Helicobacter pylori infection[J]. Dig Liver Dis, 2022, 54(12): 1630-1638. doi: 10.1016/j.dld.2022.03.007
[28]	Wu Q, Chen J, Deng H, et al. Expert-level diagnosis of nasal polyps using deep learning on whole-slide imaging[J]. J Allergy Clin Immunol, 2020, 145(2): 698-701. e6. doi: 10.1016/j.jaci.2019.12.002
[29]	刘毅然. 基于舌象的胃肠道疾病智能诊断系统研究[D]. 济南: 山东大学, 2024.